|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||6.10 / 7.01|
Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.
From small-cap genetics and biotech firms to large-cap drug distributors and pharmacies, eight experts select their top picks in the space for this year.
These four biotech stocks have been moving on some interesting news and clinical results.
There really is no such thing as "bad news" right now because there are buyers regardless.
Market has been slow but steady with no overtly negative action.
We would look to go long VA on a $39 buy-stop using a $34 sell-stop.
The market seems to be severely discounting DynaVax's chances of approval for its hep-B treatment.
We're establishing a new position in Zillow, and making a number of other adjustments.
Here we go. By Bret Jensen The market is slightly up across the board in the first 30 minutes of trading, and the 10-year Treasury yield is approaching 2.65%. Deckers Outdoor (DECK) is nicely up due to an upgrade at Wells Fargo, which now has price ...
Political squabbling in the U.S. and in Italy has pushed stocks down globally. Achillion Pharma plunges as Apple Beats Coke on branding.
Its been a busy summer for biotech, but the coming weeks will heat up with trials from Biodel, Achillon and Coronado, says Adam Feuerstein, Sr. Columnist at TheStreet.